Child Pneumococcal Serotype Epidemiology In Greece

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

457 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-11-30

Study Completion Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Streptococcus pneumoniae is a major cause of pneumonia, sepsis, bacteremia, and pneumococcal meningitis among infants and children worldwide. The 7-valent conjugate pneumococcal vaccine (Prevenar) has been introduced in the Greek Market in 2004. Additionally, as of 2006 Prevenar has been included in the Greek National Immunization Program.

The effect of the mass vaccination on the incidence of pneumococcal serotypes involved in the occurring invasive pneumococcal disease, is an important factor to consider for the introduction of the 13-valent pneumococcal conjugate vaccine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunological Memory Against Pneumococcus Induced by 3 Infant PCV 13 Vaccination Schedules

NCT03405805

Immunogenicity, Vaccine Immunologic Memory

UNKNOWN

Long-term Impact of Pneumococcal Conjugate Vaccine on Carriage

NCT00294021

Pneumococcal Infections

COMPLETED

Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome

NCT01346007

Idiopathic Nephrotic Syndrome

UNKNOWN PHASE4

Effect of Two Versus Three Pneumococcal Conjugate Vaccinations

NCT00189020

Streptococcus Pneumoniae Infection

COMPLETED PHASE3

Evaluating Vaccine Responses in Healthy Infants Receiving Their Routine Primary Immunisation According to the Accelerated United Kingdom Schedule at 2, 3 and 4 Months

NCT01425372

Streptococcus Pneumoniae

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

open label, one group Purposive sampling of hospitalized children ≤14 years of age with confirmed IPD

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumococcal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group 1

Hospitalized children ≤14 years of age with invasive pneumococcal disease

no intervention

Intervention Type OTHER

There is no intervention. This is a non interventional study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no intervention

There is no intervention. This is a non interventional study.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children aged 14 years old or less.
* Hospitalized in a participating healthcare facility with an IPD.
* IPD will be confirmed by isolation of S. pneumoniae from a sterile body site.